tradingkey.logo
tradingkey.logo
Suchen

Maravai LifeSciences Holdings Inc

MRVI
Zur Watchlist hinzufügen
4.335USD
-0.035-0.80%
Trading geöffnet ETKurse um 15 Minuten verzögert
639.40MMarktkapitalisierung
VerlustKGV TTM

Maravai LifeSciences Holdings Inc

4.335
-0.035-0.80%

mehr Informationen über Maravai LifeSciences Holdings Inc Unternehmen

Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.

Maravai LifeSciences Holdings Inc Informationen

BörsenkürzelMRVI
Name des UnternehmensMaravai LifeSciences Holdings Inc
IPO-datumNov 20, 2020
CEOBrust (Bernd)
Anzahl der mitarbeiter570
WertpapierartOrdinary Share
GeschäftsjahresendeNov 20
Addresse10770 Wateridge Circle Suite 200
StadtSAN DIEGO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl92121
Telefon18585460004
Websitehttps://www.maravai.com/
BörsenkürzelMRVI
IPO-datumNov 20, 2020
CEOBrust (Bernd)

Führungskräfte von Maravai LifeSciences Holdings Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Bernd Brust
Mr. Bernd Brust
Chief Executive Officer, Director
Chief Executive Officer, Director
2.00M
--
Mr. Rajesh J. (Raj) Asarpota
Mr. Rajesh J. (Raj) Asarpota
Chief Financial Officer
Chief Financial Officer
500.00K
--
Ms. Christine Dolan
Ms. Christine Dolan
Executive Vice President, General Manager - Cygnus Technologies
Executive Vice President, General Manager - Cygnus Technologies
429.95K
+27.80%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Chairman of the Board
Independent Chairman of the Board
365.89K
+63.27%
Mr. Kurt Oreshack
Mr. Kurt Oreshack
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
316.63K
-28.85%
Mr. Gregory T. (Greg) Lucier
Mr. Gregory T. (Greg) Lucier
Independent Director
Independent Director
264.91K
+33.65%
Ms. Susannah Gray
Ms. Susannah Gray
Independent Director
Independent Director
169.91K
--
Mr. Luke Joseph Marker
Mr. Luke Joseph Marker
Director
Director
138.06K
--
Mr. Constantine S. (Dean) Mihas
Mr. Constantine S. (Dean) Mihas
Director
Director
--
--
Mr. Sean L. Cunningham
Mr. Sean L. Cunningham
Director
Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Bernd Brust
Mr. Bernd Brust
Chief Executive Officer, Director
Chief Executive Officer, Director
2.00M
--
Mr. Rajesh J. (Raj) Asarpota
Mr. Rajesh J. (Raj) Asarpota
Chief Financial Officer
Chief Financial Officer
500.00K
--
Ms. Christine Dolan
Ms. Christine Dolan
Executive Vice President, General Manager - Cygnus Technologies
Executive Vice President, General Manager - Cygnus Technologies
429.95K
+27.80%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Chairman of the Board
Independent Chairman of the Board
365.89K
+63.27%
Mr. Kurt Oreshack
Mr. Kurt Oreshack
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
316.63K
-28.85%
Mr. Gregory T. (Greg) Lucier
Mr. Gregory T. (Greg) Lucier
Independent Director
Independent Director
264.91K
+33.65%

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Apr 6
Währung: USDAktualisiert: Mon, Apr 6
FY2025
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
North America
112.38M
60.50%
Asia Pacific
41.47M
22.33%
Europe, the Middle East and Africa
30.92M
16.65%
Latin and Central America
971.00K
0.52%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: 17 hours ago
Aktualisiert: 17 hours ago
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
GTCR Golder Rauner, LLC
13.66%
12 West Capital Management, L.P.
6.05%
Braidwell LP
5.66%
Hudson View Capital LLC
5.41%
BlackRock Institutional Trust Company, N.A.
5.38%
Andere
63.84%
Aktionäre
Aktionäre
Anteil
GTCR Golder Rauner, LLC
13.66%
12 West Capital Management, L.P.
6.05%
Braidwell LP
5.66%
Hudson View Capital LLC
5.41%
BlackRock Institutional Trust Company, N.A.
5.38%
Andere
63.84%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
29.84%
Hedge Fund
24.12%
Investment Advisor/Hedge Fund
17.84%
Private Equity
13.66%
Individual Investor
6.46%
Corporation
5.41%
Research Firm
4.69%
Pension Fund
0.20%
Bank and Trust
0.12%

Institutionelle Beteiligung

Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
476
140.69M
95.39%
-29.12M
2025Q4
498
130.99M
90.33%
-38.49M
2025Q3
518
128.65M
88.93%
-44.43M
2025Q2
560
144.27M
100.21%
-25.80M
2025Q1
589
133.65M
92.84%
-44.45M
2024Q4
580
144.56M
101.93%
-33.57M
2024Q3
603
148.21M
104.79%
-33.05M
2024Q2
611
152.09M
114.44%
-19.50M
2024Q1
609
139.87M
105.40%
-26.88M
2023Q4
621
137.21M
103.78%
-26.31M
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
GTCR Golder Rauner, LLC
20.15M
13.77%
--
--
Dec 31, 2025
12 West Capital Management, L.P.
8.92M
6.09%
-3.60M
-28.75%
Dec 31, 2025
Braidwell LP
8.35M
5.71%
--
--
Dec 31, 2025
Hudson View Capital LLC
7.98M
5.45%
-961.72K
-10.76%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
7.94M
5.42%
+248.40K
+3.23%
Dec 31, 2025
T. Rowe Price Investment Management, Inc.
6.34M
4.33%
+178.44K
+2.90%
Dec 31, 2025
Mackenzie Financial Corporation
6.17M
4.22%
+104.36K
+1.72%
Dec 31, 2025
Renaissance Technologies LLC
4.23M
2.89%
-93.00K
-2.15%
Dec 31, 2025
Tejara Capital Ltd.
3.02M
2.06%
+566.77K
+23.10%
Dec 31, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Tue, Dec 2
Aktualisiert: Tue, Dec 2
Name
Anteil
Global X Genomics & Biotechnology ETF
0.41%
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
Mehr Anzeigen
Global X Genomics & Biotechnology ETF
Anteil0.41%
Invesco Nasdaq Biotechnology ETF
Anteil0.05%
ProShares Ultra Nasdaq Biotechnology
Anteil0.04%
iShares Biotechnology ETF
Anteil0.03%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0.03%
iShares Russell 2000 Value ETF
Anteil0.02%
Schwab U.S. Small-Cap ETF
Anteil0.01%
iShares Russell 2000 ETF
Anteil0.01%
Proshares Ultra Russell 2000
Anteil0.01%
ProShares Hedge Replication ETF
Anteil0.01%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI